Literature DB >> 3369975

Methylprednisolone and multiple sclerosis.

A Compston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3369975     DOI： 10.1001/archneur.1988.00520300089025

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  5 in total

1.  Arachidonic and docosahexanoic acid content of bovine brain myelin: implications for the pathogenesis of multiple sclerosis.

Authors:  K A Ansari; D W Shoeman
Journal:  Neurochem Res       Date:  1990-01       Impact factor: 3.996

2.  Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study.

Authors:  Ariella L G Coler-Reilly; Tomoo Sato; Toshio Matsuzaki; Masanori Nakagawa; Masaaki Niino; Masahiro Nagai; Tatsufumi Nakamura; Norihiro Takenouchi; Natsumi Araya; Naoko Yagishita; Eisuke Inoue; Yoshihisa Yamano
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.

Authors:  N L Banik; D Matzelle; E Terry; G Gantt-Wilford; E L Hogan
Journal:  Neurochem Res       Date:  2000-11       Impact factor: 3.996

4.  Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

Authors:  F Barkhof; M W Tas; S T Frequin; P Scheltens; O R Hommes; J J Nauta; J Valk
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

5.  The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation.

Authors:  Franz Felix Konen; Ulrich Wurster; Torsten Witte; Konstantin Fritz Jendretzky; Stefan Gingele; Hayrettin Tumani; Kurt-Wolfram Sühs; Martin Stangel; Philipp Schwenkenbecher; Thomas Skripuletz
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.